期刊
ACS NANO
卷 13, 期 5, 页码 5356-5365出版社
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.8b09829
关键词
ovarian cancer; cancer imaging; fluorescence-guided surgery; M13 bacteriophage; microscopic cancer debulking; survival improvement
类别
资金
- National Cancer Institute [P30-CA14051]
- Koch Institute for Integrative Cancer Research at MIT
- Dana-Farber/Harvard Cancer Center (DF/HCC)
- Milano Bicocca University
- Koch Institute Marlena Felter Bradford Research Travel Fellowship
- Mazumdar-Shaw International Oncology Fellowship
- Koch Institute's Marble Center for cancer Nanomedicine
- Julie Fund
- Gynecologic Cancer Translational Research Fund
Improved cytoreductive surgery for advanced stage ovarian cancer (OC) represents a critical challenge in the treatment of the disease. Optimal debulking reaching no evidence of macroscopic disease is the primary surgical end point with a demonstrated survival advantage. Targeted molecule-based fluorescence imaging offers complete tumor resection down to the microscopic scale. We used a custom-built reflectance/fluorescence imaging system with an orthotopic OC mouse model to both quantify tumor detectability and evaluate the effect of fluorescence image-guided surgery on postoperative survival. The contrast agent is an intraperitoneal injectable nanomolecular probe, composed of single-walled carbon nanotubes, coupled to an M13 bacteriophage carrying modified peptide binding to the SPARC protein, an extracellular protein overexpressed in OC. The imaging system is capable of detecting a second near-infrared window fluorescence (1000-1700 nm) and can display real-time video imagery to guide intraoperative tumor debulking. We observed high microscopic tumor detection with a pixel-limited resolution of 200 mu m. Moreover, in a survival-surgery orthotopic OC mouse model, we demonstrated an increased survival benefit for animals treated with fluorescence image guided surgical resection compared to standard surgery.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据